ArticleJCO global oncology2021
Tackling Diversity in Prostate Cancer Clinical Trials: A Report From the Diversity Working Group of the IRONMAN Registry.
Article in JCO global oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
Analyzing Clinical Trial Experiences of Prostate Cancer Patients To Determine How Trial Attributes Affect Completion Rates For Specific Demographic Groups
Who cites it
19 citing papers in PubMed, 25 citations in OpenAlex.
- Assessing Algorithmic Fairness With a Multimodal Artificial Intelligence Model in Men of African and Non-African Origin on NRG Oncology Prostate Cancer Phase III Trials.JCO clinical cancer informatics · 2025Trial
- Trainee and Faculty Perspectives on Global Oncology: Assessing Interest, Barriers, and Opportunities.Journal of cancer education : the official journal of the American Association for Cancer Education · 2026Article
- Near-Real-Time Clinical Trial Accrual Dashboard in a National Cancer Institute-Designated Cancer Center: Mixed Methods Implementation Study.JMIR medical informatics · 2026Article
- Drivers Influencing Prostate Cancer Treatment Decision making - A Qualitative Analysis of Underrepresented Men across the US.Journal of racial and ethnic health disparities · 2025Article
- Is it time for Canada to revisit its approach to prostate cancer screening?Lancet regional health. Americas · 2025Review
- Addressing diversity barriers in prostate cancer clinical trials for equitable healthcare outcomes.Nature reviews. Urology · 2025Article
- Gaps in diversity and inclusion reporting in United States knee injury clinical trials: A systematic review and meta-analysis.Journal of experimental orthopaedics · 2025Review
- Development and validation of a nomogram for predicting clinically significant prostate cancer using serologic indices, multiparametric magnetic resonance imaging, and sound touch elastography parameters: a retrospective study.Frontiers in oncology · 2025Article
- Review
- Considerations from employed African-American and white prostate cancer survivors on prostate cancer treatment and survivorship: a qualitative analysis.Ethnicity & health · 2024Article
- Marital Status, Living Arrangement, and Survival among Individuals with Advanced Prostate Cancer in the International Registry for Men with Advanced Prostate Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024Article
- Advances in multiparametric magnetic resonance imaging combined with biomarkers for the diagnosis of high-grade prostate cancer.Frontiers in surgery · 2024Review
- Prostate-specific antigen response and clinical progression-free survival in Black and White men with chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide in a real-world setting.Prostate cancer and prostatic diseases · 2023Article
- IRONMAN: A Novel International Registry of Men With Advanced Prostate Cancer.JCO global oncology · 2022Article
- Review
- A patient-driven clinicogenomic partnership for metastatic prostate cancer.Cell genomics · 2022Article
- Racial disparities in prostate cancer: A complex interplay between socioeconomic inequities and genomics.Cancer letters · 2022Article
- Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive Prostate Cancer.The oncologist · 2022Article
- Prostate cancer immunotherapy: a review of recent advancements with novel treatment methods and efficacy.American journal of clinical and experimental urology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 16 institutions in 3 countries.
Funding
Abstract
Prostate cancer disproportionately affects racial and ethnic minority populations. Reasons for disparate outcomes among minority patients are multifaceted and complex, involving factors at the patient, provider, and system levels. Although advancements in our understanding of disease biology have led to novel therapeutics for men with advanced prostate cancer, including the introduction of biomarker-driven therapeutics, pivotal translational studies and clinical trials are underrepresented by minority populations. Despite attempts to bridge the disparities gap, there remains an unmet need to expand minority engagement and participation in clinical trials to better define the impact of therapy on efficacy outcomes, quality of life, and role of biomarkers in diverse patient populations. The IRONMAN registry (ClinicalTrials.gov identifier: NCT03151629), a global, prospective, population-based study, was borne from this unmet medical need to address persistent gaps in our knowledge of advanced prostate cancer. Through integrated collection of clinical outcomes, patient-reported outcomes, epidemiologic data, and biospecimens, IRONMAN has the goal of expanding our understanding of how and why prostate cancer outcomes differ by race and ethnicity. To this end, the Diversity Working Group of the IRONMAN registry has developed informed strategies for site selection, recruitment, engagement and retention, and trial design and eligibility criteria to ensure broad inclusion and needs awareness of minority participants. In concert with systematic strategies to tackle the complex levels of disparate care, our ultimate goal is to expand minority engagement in clinical research and bridge the disparities gap in prostate cancer care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.